<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221119056535N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-18</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of Remifentanil and Labtalol on hemodynamic changes</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Remifentanil and Labtalol, in combination with Propofol, on hemodynamic changes in nasal endoscopy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66917</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who met the necessary conditions, after completing the personal informed consent form to the trial in a simple random manner using blue and red color cards placed in a container and the patient himself chooses the color of his choice. They enter one of the two experimental and control groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Hemodynamic changes. Condition 2: Bleeding rate. Condition 3: arrhythmia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Patients who met the necessary conditions, after full training by an anesthesiologist and filling in the patient's informed personal consent form, entered the study and were randomly assigned to experimental group A (remifentanil combined with propofol). Dose of drugs: Remifentanil: the onset of anesthesia starts with 1 to 5 mcg/kg/minute. If an endotracheal tube is inserted for the patient within 8 minutes, an initial dose of 1 mcg/kg in 30-60 Seconds are also given to maintain anesthesia: 1 mcg/kg/min can be infused every 2-5 minutes. The dose can be increased by 25-100% or decreased by 25-50% every 2-5 minutes. Propofol: within 15 seconds and with a dose of 2 mg/kg based on the weight of the study group, it is injected through a tee along with 10 cc of normal saline. Intervention 2: Intervention group 2: Patients who met the necessary conditions, after full training by the anesthesiologist and filling out the patient's informed personal consent form, entered the study and were randomly assigned to experimental group B (labtalol in combination with propofol). Dosage of drugs: labtalol: 20 mg intravenous injection once and then, if there is no effect, as an infusion of 2-0.5 mg per minute up to a maximum dose of 300 mg and propofol: within 15 seconds and with a dose of 2 mg/kg based on The weight of the study group is injected with 10 cc of normal saline through a tee.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Need more advice</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khashayar Shahverdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, Floor 10, Kasra 5, Nokhbegan square</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3415866563</zip>
        <telephone>+98 21 2270 7778</telephone>
        <email>kh.shahverdi@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khashayar Shahverdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, Floor 10, Kasra 5, Nokhbegan square</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3415866563</zip>
        <telephone>+98 21 2270 7778</telephone>
        <email>kh.shahverdi@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in research with informed consent after giving necessary and sufficient explanations about the study
The age of the person should be between 15 and 60 years
There is no history of surgery and it is the patient's first surgery
Not having a chronic mental or physical illness (schizophrenia, diabetes, etc.)
Not having vision and hearing problems and other disabilities
No allergy to Remifentanil, Profol and Labtalol
Absence of pregnancy, breastfeeding and abortion less than 3 months</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Heart diseases and HTN
Liver diseases (cirrhosis, hepatitis, etc.)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code>I49.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Cardiac arrhythmia, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients who met the necessary conditions, after full training by an anesthesiologist and filling in the patient's informed personal consent form, entered the study and were randomly assigned to experimental group A (remifentanil combined with propofol). Dose of drugs: Remifentanil: the onset of anesthesia starts with 1 to 5 mcg/kg/minute. If an endotracheal tube is inserted for the patient within 8 minutes, an initial dose of 1 mcg/kg in 30-60 Seconds are also given to maintain anesthesia: 1 mcg/kg/min can be infused every 2-5 minutes. The dose can be increased by 25-100% or decreased by 25-50% every 2-5 minutes. Propofol: within 15 seconds and with a dose of 2 mg/kg based on the weight of the study group, it is injected through a tee along with 10 cc of normal saline.</i_keyword>
      <i_keyword>Intervention group 2: Patients who met the necessary conditions, after full training by the anesthesiologist and filling out the patient's informed personal consent form, entered the study and were randomly assigned to experimental group B (labtalol in combination with propofol). Dosage of drugs: labtalol: 20 mg intravenous injection once and then, if there is no effect, as an infusion of 2-0.5 mg per minute up to a maximum dose of 300 mg and propofol: within 15 seconds and with a dose of 2 mg/kg based on The weight of the study group is injected with 10 cc of normal saline through a tee</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding. Timepoint: First, three minutes after the start of induction, then three and five minutes and then ten minutes. Method of measurement: ECG, pulse oximeter, non-invasive blood pressure measurement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-16</approval_date>
        <contact_name>Ethics Committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Unit 1, 10 floor, Kasra tower 5, Nokhbegan square Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
